Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  XenoPort, Inc.    XNPT

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

XenoPort, Inc. : XenoPort Announces New Employment Inducement Award

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/01/2012 | 11:05pm CEST

XenoPort, Inc. (Nasdaq:XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee, Sayuri Ino, was granted restricted stock units representing an aggregate of 500 shares of XenoPort's common stock. The restricted stock units vest in four equal annual installments on anniversaries of the June 1, 2012 grant date. The equity award was approved by the independent compensation committee of XenoPort's board of directors and was granted as an inducement material to the new employee entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4).

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is XenoPort's first U.S. Food and Drug Administration-approved product. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of moderate-to-severe primary restless legs syndrome in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with postherpetic neuralgia, spasticity and Parkinson's disease.

To learn more about XenoPort, please visit the company Website at www.XenoPort.com.

Horizant is a registered U.S. trademark of GSK.

XENOPORT is a registered trademark of XenoPort, Inc.

Regnite is a registered trademark of Astellas.

XNPT2G

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on XENOPORT, INC.
2016 XENOPORT INC : Completion of Acquisition or Disposition of Assets, Notice of Del..
2016 XENOPORT : Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of..
2016 LAWSUIT FOR INVESTORS IN XENOPORT, I : XNPT) in Effort to Halt Acquisition Filed
2016 XENOPORT : Report Summarizes Restless Legs Syndrome Study Findings from XenoPort..
2016 XENOPORT : New Postherpetic Neuralgia Study Results from XenoPort, Inc. Describe..
2016 XENOPORT : Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR..
2016 XENOPORT : XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategi..
2016 XENOPORT : Why Xenoport, Inc. Stock Jumped 61.1% in May
2016 XENOPORT : Research Conducted at XenoPort, Inc. Has Provided New Information abo..
2016 XENOPORT : BioSurplus To Auction Research Equipment from the Laboratories of Xen..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2016 New Oral Psoriasis Drug Tops Cellceutix Catalysts
2016 Biotechnology - The Perfect Yo-Yo
2016 Is This The Next REIT To Return 50%?
2016 Jay Z Sells Out To Apple
2016 GE's Next Big Energy Move
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Vincent J. Angotti Chief Executive Officer & Director
William G. Harris Chief Financial Officer & Senior VP-Finance
Richard K. Kim Chief Medical Officer & SVP-Clinical Development
William J. Rieflin Director
Jeryl L. Hilleman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
XENOPORT, INC.0.00%0
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results